812results about "Peptide sources" patented technology

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts antithrombotic effects. The antibody of the present invention has suitable antithrombotic properties, has a wide effective therapeutic concentration window, but does not increase the risk of bleeding; it can realize the demand for moderate antithrombotic properties in clinical applications and effectively avoid bleeding problems caused by excessive effects. The present invention also discloses a method for screening drugs that target the FIXa-FVIIIa binding site.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.

Disclosed are antigen-binding molecules, chimeric receptors, and engineered immune cells according to the present invention. The present invention also relates to vectors, compositions, and treatment and / or detection methods using the antigen-binding molecules and engineered immune cells.

To provide improved beneficial bacteria that can suppress the growth of pathogens.SOLUTION: The present disclosure provides, inter alia, an optimized strain of Nitrosomonas eutropha (N. eutropha) designated D23, D23-100, or AOB D23-100. N. eutropha bacteria disclosed in the present application have desirable properties, e.g., optimized properties, such as the ability to suppress growth of pathogenic bacteria, and an enhanced ability to produce nitric oxide and nitric oxide precursors. The N. eutropha herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.SELECTED DRAWING: Figure 18

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

Provided is a nucleic acid structure which enhances an antigen-specific immune response. The nucleic acid structure comprises a polynucleotide encoding a SNARE protein selected from the group consisting of VAMP7, GOSR2, STX10, STX18, BNIP1, STX7, VTI1A, STX16, STX5, GOSR1, STX8, STX12, VAMP8 and SEC22B, and a polynucleotide encoding an antigen.

The invention belongs to the technical field of cell engineering, and particularly relates to a construction method and application of a mammal rapamycin target protein self-activated mouse model and a mouse embryo fibroblast line. According to the invention, serine (Serine, S) at site 2215 of mTOR protein is mutated into tyrosine (Tyrosine, Y), and a transgenic mouse model with activation mutation of mTORS2215Y, namely a mouse model with self-activation of mammal rapamycin target protein, is constructed. A mouse embryo fibroblast line which can be immortalized is constructed by utilizing the transgenic mouse model, so that the related mechanism research of mTOR self-activation mutation can be carried out at the cellular level, and the screening of related therapeutic drugs can be carried out.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present application discloses a use of an antigen short peptide in the screening of a drug for treating an HPV-related disease, and a T cell receptor (TCR) screened by the antigen short peptide. An amino acid sequence of the antigen short peptide is represented by SEQ ID NO: 1. The antigen short peptide of the present application can screen a specific TCR, T cells transduced with the TCR can be specifically activated and have a strong killing effect on tumor cells which express A1101 and HPV, and the TCR can be used for immunotherapy of HPV-positive tumors such as cervical cancer. Moreover, the T cells transduced with the TCR of the present application have a strong activation reaction on a cell line which expresses E7, have no activation reaction on a cell line which does not express E7, have a very strong killing function on the cell line which expresses E7, and can effectively inhibit the growth of E7-positive tumors.

The present invention relates to a recombinantly constructed protein that is useful for analytical assay, particularly for determining the presence of rhabdovirus specific antibody in biological samples obtained from individuals.More specifically, the present invention relates to a polypeptide that comprises the ectodomain of rhabdovirus glycoprotein and the heterologous multimerization domain connected to said ectodomain.In one example, there is provided a fusion protein of formula xyz (wherein x consists of or comprises the ectodomain, which may not contain furin cleavage site, y is a linker site, and z is the heterologous multimerization domain that may be selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence and avidin sequence).

The present disclosure relates to a cleavable carrier and a cytokine prodrug conjugated to the cleavable carrier, wherein the cleavable carrier is an engineered Fc domain comprising at least one tumor-associated protease cleavage site. Upon cleavage at the cleavage site of the carrier Fc domain, the cytokine is released from the masking moiety. This platform provides enzymatically induced prodrug activation. The present disclosure further provides a pharmaceutical composition comprising the cytokine prodrug conjugated to the cleavable carrier, its use as a medicament, and methods of treating and administering the disease.

Compositions and methods are provided for treating diseases associated with abnormal glycosylation of cell surface molecules and the expression of tumor-associated carbohydrate antigen (TACA). Also provided are a bispecific fusion protein and a chimeric antigen receptor (CAR) specific for a tumor-associated carbohydrate antigen (TACA-CAR), a vector encoding the TACA-bispecific fusion protein and the TACA-CAR, and a recombinant cell comprising the TACA-bispecific fusion protein and the TACA-CAR.

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present invention addresses the problem of providing a novel synthetic peptide having cell membrane permeability. [Solution] A synthetic peptide disclosed by the present invention comprises any one of the following amino acid sequences: (1) an amino acid sequence in which two or more minimum structural units are continuously bonded in series, said minimum structural units having GD (glycine residue-aspartic acid residue) or GE (glycine residue-glutamic acid residue) as the minimum structural units; and (2) an amino acid sequence obtained by binding 1-3 glycine residues to the C-terminal side of the amino acid sequence of (1).

The present invention pertains to: a granzyme B variant having enhanced protease activity and / or enhanced tolerance against an inhibitory factor; a polynucleotide encoding the granzyme B variant; a cell expressing the granzyme B variant; a pharmaceutical composition comprising the cell expressing the granzyme B variant; and a pharmaceutical composition comprising the granzyme B variant. In some embodiments, the pharmaceutical composition can be used in combination with a cell expressing a chimeric receptor and / or an antigen-binding molecule.

Therapeutic agents that can place bulky proteins, such as CD45, CD148, and CD43, at the center of the cellular interface between graft cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells) are disclosed, as are methods of their use and products made with such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immunological synapses (including physiological SMACs). They also result in the continuous dephosphorylation of signaling pathways.

In this specification, in an aspect, compositions, methods, kits and systems are disclosed relating to the efficient delivery of a freight (e.g., a therapeutic freight) to cells, for example, for in vivo delivery. More specifically, the delivery vehicle is a lipid-containing particle comprising (a) a human endogenous retrovirus (HERV) envelope protein, a humanized envelope protein, or a non-immunogenic membrane fusion molecule, (b) a combinatorial protein comprising a plasma membrane-localized protein, and (c) a freight.

The present invention relates to an improved protein-based biosensor suitable for the detection of one or more target molecules in a sample. The biosensor is fully reversible with a dynamic range suitable for analytical and diagnostic applications. The biosensor of the present invention can be used in synthetic biology, for example in the construction of artificial cellular or extracellular signaling networks.

The present invention provides a method for constructing and applying multivalent protein drugs and vaccines via nucleic acid multimerization. Specifically, the present invention provides a multimeric complex based on a complementary nucleic acid backbone, which is a multimer formed by complexing three to six monomers having a complementary nucleic acid backbone, where each monomer is a polypeptide having a single nucleic acid strand. In the multimer, the single nucleic acid strand of each monomer and the single nucleic acid strands of the other two monomers form a double strand through base complementarity, thereby forming a complementary nucleic acid backbone structure. The present invention also provides a pharmaceutical composition containing the multimeric complex, a nucleic acid sequence library for constructing the multimeric complex, and a method for optimizing the complementary nucleic acid backbone. The present invention also provides a method for completing the multivalency of off-the-shelf short-acting protein drugs or antigens, improving their half-life, activity, and / or immunogenicity, without the need for fusion protein reconstruction or chemical modification and crosslinking.

The present invention relates to the use of a polypeptide in resisting addiction and its relapse.The present invention provides the use of a polypeptide in preparing a medicament for treating and / or preventing substance addiction and its relapse.The polypeptide consists of at least 11 consecutive amino acid residues of the sequence shown in SEQ ID NO:1 and comprises the sequence shown in SEQ ID NO:2.Furthermore, the present invention relates to the use of said polypeptide, the use of a nucleic acid molecule, the use of an expression vector and the use of a host cell, as well as a complex comprising said polypeptide.

The present invention relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. Specifically, the present invention relates to the immunotherapy of cancer, particularly hematological tumors such as acute myeloid leukemia (AML). Furthermore, the present invention relates to tumor-associated T cell peptide epitopes that can be used, for example, as active pharmaceutical ingredients in vaccine compositions to stimulate anti-tumor immune responses or that can stimulate ex vivo T cells for transfer into patients. Peptides bound to major histocompatibility complex (MHC) molecules, and even the peptides themselves, may be targets for antibodies, soluble T cell receptors, and other binding molecules.

This peptide includes an amino acid sequence represented by formula A1 or an amino acid sequence in which one or more amino acid residues in the amino acid sequence represented by formula A1 have been substituted, deleted, added, or inserted. A1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15

To provide compositions and particles for payload delivery.SOLUTION: The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell. The present invention provides a composition comprising e.g., a carrier capable of entering a polarized epithelial cell or transcytosing across a polarized epithelial cell; and a heterologous payload, a molar ratio of the heterologous payload to the carrier being greater than 1:1.SELECTED DRAWING: None